Medicenna Therapeutics (TSX:MDNA) Net Change in Cash : C$-14.40 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Medicenna Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Medicenna Therapeutics's Net Change in Cash for the three months ended in Dec. 2023 was C$-3.93 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was C$-14.40 Mil.

Medicenna Therapeutics Net Change in Cash Historical Data

The historical data trend for Medicenna Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicenna Therapeutics Net Change in Cash Chart

Medicenna Therapeutics Annual Data

Trend

Dec15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Net Change in Cash

Get a 7-Day Free Trial

-1.54

20.33

7.68

-9.84

13.06

Medicenna Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Change in Cash	Get a 7-Day Free Trial															-3.86	-2.56	-3.98	-3.93	-3.93

Medicenna Therapeutics Net Change in Cash Calculation

Medicenna Therapeutics's Net Change in Cash for the fiscal year that ended in Mar. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-12.657	+	0	+	24.76	+	0.958
	=	13.06

Medicenna Therapeutics's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -4.026 + 0 + 0 + 0.097

= -3.93

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-14.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicenna Therapeutics Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Medicenna Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Medicenna Therapeutics (TSX:MDNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (TSX:MDNA) » Definitions » Net Change in Cash

Comparable Companies

TSX:RVX TSXV:SBM XCNQ:DOSE TSXV:NRX NEOE:BMND TSXV:IBT XCNQ:MDMA XCNQ:COOL XCNQ:TELI TSXV:COV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Traded in Other Exchanges

MDNAF:USA

Address

2 Bloor Street W., 7th Floor, Toronto, ON, CAN, M4W 3E2

Website

https://www.medicenna.com

Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.

Medicenna Therapeutics (TSX:MDNA) Headlines

No Headlines